Anna Kopp

Statistics

Publications

Citations

299

H-Index

Active since

2020

Affiliations

University of Michigan(Current)

ImmunoGen (United States)

Immunomedics (United States)

Michigan Center for Translational Pathology

Anna Kopp is an author at University of Michigan specializing in antibody-drug conjugate pharmacokinetics, antibody-drug conjugates, and targeted cancer therapy.

ORCID

Publications per year

2020–2023

Publications

Increased Tumor Penetration of Single-Domain Antibody–Drug Conjugates Improves <i>In Vivo</i> Efficacy in Prostate Cancer Models

Ian Nessler, Eshita Khera, Steven Vance et al. · Cancer Research · 2020 · 127 citations · Full text

Pharmacy, Pharmaceutics, Pharmacokinetics +17

Antibody–Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release

Anna Kopp, Scott Hofsess, Thomas M. Cardillo et al. · Molecular Cancer Therapeutics · 2022 · 91 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Quantifying ADC bystander payload penetration with cellular resolution using pharmacodynamic mapping

Eshita Khera, Cornelius Cilliers, Michael D. Smith et al. · Neoplasia · 2020 · 52 citations · Full text

Medicine, Oncology, Pharmacology +17

Improving Intracellular Delivery of an Antibody–Drug Conjugate Targeting Carcinoembryonic Antigen Increases Efficacy at Clinically Relevant Doses <i>In Vivo</i>

Ian Nessler, Baron Rubahamya, Anna Kopp et al. · Molecular Cancer Therapeutics · 2023 · 15 citations · Full text

Pharmacy, Molecular Pharmaceutics, Oncology +17

Predictive Simulations in Preclinical Oncology to Guide the Translation of Biologics

Shujun Dong, Ian Nessler, Anna Kopp et al. · Frontiers in Pharmacology · 2022 · 14 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

1–5 of 5